Abstract
In the past decade, it has become increasingly clear that proinflammatory cytokines play a prominent role in the pathophysiology of sepsis. Of these, tumor necrosis factor α (TNF-α) and interleukin 1 (IL-1) seem to be of particular importance. Administration of either TNF-α or IL-1 to experimental animals results in a syndrome that mimics sepsis, and therapy specifically directed against either cytokine protects against lethality in experimental sepsis and endotoxe- mia. In recent years, several endogenous mechanisms meant to protect the host against excessive activity of these highly potent cytokines have been identified. In this chapter, we will briefly discuss current knowledge of the roles of TNF and IL-1 in the pathogenesis of sepsis, and will provide an overview of endogenous mechanisms, that regulate the production and activities of TNF and IL-1.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Van der Poll T, Lowry SF (1995) Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock (in press)
Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627–1652
Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13: 151–153
Sims JE, Giri JG, Dower SK (1994) The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 72: 9–14
Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1: 355–357
Girardin E, Grau GE, Dayer JM, and the J5 Study Group (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319: 397–400
Lowry SF, Calvano SE, van der Poll T (1995) Measurement of inflammatory mediators in clinical sepsis. In: Sibbald WJ, Vincent JL (eds) Clinical Trials for the Treatment of Sepsis. Springer-Verlag, Heidelberg, Vol 19, pp 86–105
Hesse DG, Tracey KJ, Fong Y, et al (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166: 147–153
Fong Y, Marano MA, Moldawer LL, et al (1990) The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85: 1896–1904
Fong Y, Tracey KJ, Moldawer LL, et al (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med 170: 1627–1633
Tracey KJ, Lowry SF, Fahey III TJ, et al (1987) Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 164: 415–422
Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81: 1162–1172
Van der Poll T, Büller HR, ten Cate H, et al (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322: 1622–1627
Van der Poll T, Levi M, Büller HR, et al (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174: 729–732
Van der Poll T, van Deventer SJH, Hack CE, et al (1992) Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood 79: 693–698
Van der Poll T, Romijn JA, Endert E, Borm JJ, Büller HR, Sauerwein HP (1991) Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 261: E457–E465
Echtenacher B, Falk W, Mannel DN, et al (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145: 3762–3766
Zanetti G, Heumann D, Gérain J, et al (1992) Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-α and to lipopolysaccharide. J Immunol 148: 1890–1897
Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxic shock. Nature 348: 550–552
Fischer E, Marano MA, van Zee KJ, et al (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551–1557
Aiura K, Gelfand JA, Wakabayashi G, et al (1991) Interleukin-1 receptor antagonist blocks staphylococcal-induced shock in rabbits. Cytokine 3: 498–507
Fisher Jr CJ, Dhainaut JFA, Opal SM, et al (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836–1840
Moore KW, O’Garra A, de Waal-Malefyt R, Vieira P, Mosmann TR (1993) Interleukin 10. Ann Rev Immunol 11: 165–190
Marchant A, Devière J, Byl B, de Groote D, Vincent JL, Goldman M (1994) Interleukin- 10 production during septicaemia. Lancet 343: 707–708
Van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJH (1995) Regulation of interleukin-10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (in press)
Marchant A, Bruyns C, Vandenabeele P, et al (1994) IL-10 controls IFN-γ and TNF production during experimental endotoxemia. Eur J Immunol 24: 1167–1171
Van der Poll T, Marchant A, Berman L, et al (1995) Endogenous interleukin-10 protects against death in septic peritonitis in mice. Surg Forum (in press)
Gérard C, Bruyns C, Marchant A, et al (1993) Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547–550
Leeuwenberg JFM, Jeunhomme TMAA, Buurman WA (1994) Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 152: 4036–4040
Schindler R, Mancilla J, Endres S, Ghorbani R, Clark R, Dinarello CA (1990) Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75: 40–47
Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW (1994) Interleukin-6 (IL-6) as an antiinflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113–118
Libert C, Vink A, Coulie P, et al (1992) Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol 22: 2625–2630
Van der Poll T, Levi M, Hack CE, et al (1994) Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179: 1253–1259
Santos AA, Scheltinga MR, Lynch E, et al (1993) Elaboration of interleukin-1 receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 128: 138–144
Barber AE, Coyle SM, Marano MA, et al (1993) Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 150: 1999–2006
Severn A, Rapson NT, Hunter CA, Liew FY (1992) Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 148: 3441–3445
Van der Poll T, Jansen J, Endert E, Sauerwein HP, van Deventer SJH (1994) Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-6 production in human whole blood. Infect Immunol 62: 2046–2050
Monastra G, Secchi EF (1993) β-adrenergic receptors mediate in vivo the adrenaline inhibition of lipopolysaccharide-induced tumor necrosis factor release. Immunol (Letters) 38: 127–130
Satomi N, Sakurai A, Haranaka K (1985) Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: Role of glucose, insulin, and macrophages. J Nat Cancer Inst 74: 1255–1260
Fraker DL, Merino MJ, Norton JA (1989) Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol 256: E725–E731
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactive of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323–329
Van Zee KJ, Kohno T, Fischer E, Rock SC, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845–4849
Jansen J, van der Poll T, Levi M, et al (1995) Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor antibody. J Clin Immunol (in press)
Kuipers B, van der Poll T, Levi M, et al (1994) Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. J Immunol 152: 2438–2446
Calvano E, Thompson WA, Coyle SM, et al (1993) Changes in monocyte and soluble tumor necrosis factor (TNF) receptors during endotoxemia or sepsis. Surg Forum 44: 114–116
Granowitz EV, Porat R, Mier JW, et al (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4: 353–360
Fischer E, Van Zee KJ, Marano M, et al (1992) Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79: 2196–2200
Fischer E, Marano MA, Barber AE, et al (1991) Comparison between effects of interleu- kin-1α administration and sublethal endotoxemia in primates. Am J Physiol 261: R442–R448
Bargetzi MJ, Lantz M, Smith CG, et al (1993) Interleukin-1β induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res 53: 4010–4013
Van der Poll T, van Deventer SJH, ten Cate H, Levi M, ten Cate JW (1994) Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis 169: 665–667
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
van der Poll, T., Lowry, S.F. (1995). Endogenous Mechanisms Regulating TNF and IL-1 during Sepsis. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine. Yearbook of Intensive Care and Emergency Medicine, vol 1995. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79154-3_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-79154-3_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-58256-4
Online ISBN: 978-3-642-79154-3
eBook Packages: Springer Book Archive